A medication-use surrogate is not a direct measurement of every obstetric outcome.
A small retrospective cesarean study compared remimazolam and propofol maintenance. It examined additional uterotonic use and reported no clear estimated-blood-loss difference. Group differences in some measures were imprecise.
The analysis contained sixteen remimazolam and thirty-five propofol recipients. Additional uterotonics were given to five and nineteen patients respectively, without a clear difference in estimated blood loss. The investigators could not directly identify uterine-atony cases and used medication requirements as a proxy. A clinician’s decision to give a drug is related to, but not identical with, an objectively measured degree of uterine contraction.
The researchers could not directly identify enough uterine-atony events and used drug requirements to explore contractility concerns. Clinician treatment decisions and placental factors can influence that proxy. The study was not randomized.
Describe the measured surrogate rather than concluding that all uterine or neonatal risks were excluded. For an individual event, review the actual bleeding, uterine findings, obstetric complications and treatment timing. Similar additional-medication use does not independently establish equivalent comprehensive safety.
Source: PMC11002043, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Multimedia Bronchoscopy Information Reduced Midazolam Requirements in a Randomized Study.